Treace Medical Concepts, Inc. (TMCI) Tops Q4 EPS by 3c, provides guidance

Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q4 EPS of ($0.01), $0.03 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $68.7 million versus the consensus estimate of $67.02 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees Q1 2025 revenue of $224-230 million, versus the consensus of $225.6 million.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15